{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-112866","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.834968+00:00","generated_at":"2026-05-30T07:37:54.254424+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organon Q3 revenue $1.582B (+4% YoY); narrows FY revenue guidance upward to $6.375-6.425B","bullets":["GAAP diluted EPS $1.38; non-GAAP adjusted diluted EPS $0.87 (includes $0.16 IPR&D charge).","Women's Health +5% as-reported; Nexplanon grew 11% ex-FX; fertility +14% ex-FX.","Biosimilars +16% as-reported; Hadlima launch drove uptake; Renflexis +4% ex-FX.","FY2024 revenue midpoint raised $50M to $6.375-6.425B; Adj. EBITDA margin guide revised to 30-31%.","Established Brands +2% as-reported; flat ex-FX growth expected for full year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-112866","json":"https://secwatch.observer/filing/0001104659-24-112866.json","markdown":"https://secwatch.observer/filing/0001104659-24-112866.md","text":"https://secwatch.observer/filing/0001104659-24-112866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924112866/0001104659-24-112866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924112866/tm2427187d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:37:54.254424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}